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 2 
ABSTRACT (246 words) 48 
Exercise-induced cardiac remodeling (EICR) and the attendant myocardial adaptations 49 
characteristic of the athlete’s heart may regress during periods of exercise reduction or 50 
abstinence. The time course and mechanisms underlying this reverse remodeling, 51 
specifically the impact of concomitant plasma volume (PV) contraction on cardiac 52 
chamber size, remain incompletely understood. We therefore studied recreational runners 53 
(n=21, aged 34 ± 7 years; 48% male) who completed an 18-week training program (~7 54 
h w-1) culminating in the 2016 Boston Marathon after which total exercise exposure was 55 
confined to <2 h.w-1 (no single session >1 hour) for 8 weeks. Cardiac structure and 56 
function, exercise capacity, and PV were assessed at peak fitness (10-14 days before) and 57 
at 4- and 8-weeks post marathon. Mixed linear modeling adjusting for age, sex, V̇O2peak 58 
and marathon finish time was used to compare data across time points.  Physiologic 59 
detraining was evidenced by serial reductions in treadmill performance. Two distinct 60 
phases of myocardial remodeling and hematologic adaptation were observed. After 4 61 
weeks of detraining, there were significant reductions in PV (Δ -6.0%, P<0.01), left 62 
ventricular (LV) wall thickness (Δ -8.1%, <0.05), LV mass (Δ -10.3%, P<0.001), and 63 
right atrial area (Δ -8.2%, P<0.001). After 8 weeks of detraining, there was a significant 64 
reduction in right ventricle chamber size (end-diastolic area Δ = -8.0%, P <0.05) without 65 
further concomitant reductions in PV or LV wall thickness. Abrupt reductions in exercise 66 
training stimulus result in a structure-specific time course of reverse cardiac remodeling 67 
that occurs largely independently of PV contraction.  68 
Key Words: sports cardiology, left ventricle, cardiac morphology, echocardiography, 69 
hemoglobin mass   70 
 71 
NEW AND NOTEWORTHY (max 75 words) 72 
Significant reverse cardiac remodelling, previously documented among competitive 73 
athletes, extends to recreational runners and occurs with a distinct time course.  Initial 74 
reductions in plasma volume and LV mass, driven by reductions in wall thickness, are 75 
followed by contraction of the right ventricle. Consistent with data from competitive 76 
athletes, LV chamber volumes appear less responsive to detraining and may be a more 77 
permanent adaptation to sport. 78 
  79 
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Glossary 80 
 81 
EICR  Exercise induced cardiac remodeling 82 
LV  Left ventricle or left ventricular 83 
RV  Right ventricle or right ventricular 84 
V̇O2  Oxygen uptake 85 
V̇O2peak Peak oxygen uptake 86 
tHb-mass Total hemoglobin mass 87 
CO  Carbon monoxide 88 
[Hb]  Hemoglobin concentration 89 
COHb  Carboxyhemoglobin 90 
%COHb Percent carboxyhemoglobin 91 
PV  Plasma volume 92 
BV  Blood volume 93 
 94 
 95 
 96 
 97 
98 
 4 
INTRODUCTION  99 
 Routine vigorous endurance exercise stimulates numerous changes in 100 
cardiovascular structure and function and concomitant increases in blood volume (BV).  101 
Specifically, the process of exercise induced cardiac remodeling (EICR) is characterized 102 
by mild to moderate biventricular eccentric hypertrophy, preserved or enhanced diastolic 103 
function, bi-atrial dilation, and BV expansion. EICR has been thoroughly characterized 104 
among elite athletes (2, 11, 18, 19, 21, 33) and has recently been documented among 105 
recreational exercisers who typically perform comparatively lower volumes and 106 
intensities of exercise training (1, 8, 13, 28, 35). Similarly, the hematologic response to 107 
endurance exercise training has been described in novice exercisers where a rapid 108 
increase in plasma volume (PV) precedes a slow increase in red blood cell volume (16).  109 
A recent meta-analysis concluded that increases in red blood cell volume of 4% can be 110 
expected over 15 weeks of endurance training in young and middle aged exercisers (16). 111 
 While several studies document reductions in left ventricular (LV) wall thickness 112 
and chamber size following periods of exercise abstinence among elite competitive 113 
athletes (15, 20, 34), and during periods of bed rest in non-athletes (9), the reversibility of 114 
EICR among recreational athletes has not been described. In addition, no prior studies 115 
have described the change in blood volume that occur during exercise detraining in this 116 
population. Consequently, several key issues pertaining to EICR regression including the 117 
time course, the mechanistic role of blood volume contraction, and the response of 118 
cardiac chambers other than the left ventricle remain incompletely understood.  119 
 We therefore studied cardiac structure, function and blood volume components 120 
among recreational marathon runners who participated in an 8-week prescribed exercise 121 
detraining program following completion of a marathon race (42.2 km). We hypothesized 122 
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that participants would demonstrate significant reverse cardiac remodeling characterized 123 
by reductions in chamber volumes and wall thickness and that this reverse remodeling 124 
would parallel and perhaps be mechanistically driven by reductions in blood volume. 125 
 126 
METHODS 127 
Study Design Overview 128 
 We used a prospective, longitudinal, and repeated measures study design to 129 
examine the cardiovascular response to prescribed detraining among healthy recreational 130 
marathon runners participating in the 2016 Boston Athletic Association’s Boston 131 
Marathon (42 km foot race). An initial sample of 24 runners (50% men) were recruited 132 
and consented to this study.  No participants had established cardiovascular disease at the 133 
time of enrollment and all were free of inducible myocardial ischemia and arrhythmia 134 
during baseline cardiopulmonary exercise testing. Five female participants were routinely 135 
taking oral contraceptive pills.  Otherwise, no participants started or stopped any 136 
prescription or over-the-counter medications during the study period. In preparation for 137 
the marathon, participants completed a standardized running training program that has 138 
previously been shown to be an adequate exercise dose to stimulate exercise-induced 139 
cardiac remodeling (35), and all participants completed the marathon without medical 140 
complications. Following the marathon, participants were instructed to restrict their 141 
exercise dose to < 2 hours/week of low intensity exercise, with no single exercise session 142 
> 1 hour in duration and no interval training of any kind.  143 
   Participants underwent study measurements at 3 time points:  peak fitness at 1-2 144 
weeks prior to the marathon, 4-weeks post-race, and 8-weeks post-race (Figure 1). 145 
Assessment at each study time point included measurement of height, weight, fasting 146 
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blood sampling, cardiac structure and function using transthoracic echocardiography, 147 
maximal exercise capacity using cardiopulmonary exercise testing, and hematologic 148 
parameters using carbon monoxide rebreathing as described in detail below. The study 149 
was approved by the Partners Healthcare System Human Research Committee, and 150 
written informed consent was obtained from each participant at the time of enrollment. 151 
 152 
Exercise exposure during the study period 153 
 Self-reported exercise participation data were gathered on a weekly basis during 154 
the study period using a written questionnaire. Running distance and duration, aerobic 155 
cross training, and any other deliberate exercise training sessions were collected. Exercise 156 
exposure was categorized into running (total mileage; figure 2, panel A) and durations 157 
of: 1.) Running, 2.) Cross-training (including outdoor cycling, stationary cycling, 158 
elliptical trainer, skiing, zumba, and team sports such as soccer), 3.) Yoga or pilates, and 159 
4.) Weight training.  160 
 161 
Echocardiography 162 
 Transthoracic echocardiographic data were acquired prior to exercise testing and 163 
were completed and analyzed by a single experienced cardiac sonographer (A.D). Images 164 
were acquired using commercially available ultrasound system (Vivid-Q, GE Medical 165 
Systems, Israel Ltd), with a 1.5-4 MHz phased array transducer, to acquire 2 dimensional 166 
grey scale and Doppler images. All cardiac images were electronically archived as raw 167 
data and reported values represent the average of 3 consecutive cardiac cycles to account 168 
for heart rate and measurement variability. LV volumes, ejection fraction and left atrial 169 
volumes were calculated using the modified biplane technique (14). LV mass was 170 
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calculated using the area-length method and LV geometry was assessed using relative 171 
wall thickness. Right ventricular (RV) end-diastolic area, end-systolic area, basal 172 
diastolic diameter, diastolic length and fractional area change were measured from RV 173 
optimized apical 4-chamber images. LV myocardial tissue velocities were measured in 4 174 
basal segments (septum, lateral, inferior and anterior) and RV velocities were measured 175 
in the RV free wall base using a modified apical 4-chamber view. LV longitudinal strain 176 
was analysed using speckle tracking software (Echopac, GE Medical, Horten, Norway, 177 
version 112.1.6) of two dimensional grey-scale images taken from the apical four, two 178 
and three chamber views. In order to time-align and adjust for inter-individual variability 179 
of heart rate, frame-by-frame data were exported to custom-made software that 180 
completed cubic spline interpolation to produce 600 data points for both the systolic and 181 
diastolic periods as previously described (29, 30). All measurements are presented as raw 182 
data and after body surface area indexing via the Mosteller formula (17) where 183 
appropriate. Values defining the limits of normal right and left ventricular structure were 184 
adopted from the American Society of Echocardiography/European Association of 185 
Echocardiography chamber quantification recommendations (14). Intra and inter-186 
observer variability data from our laboratory for the key echocardiographic variables 187 
reported in this study have been previously published (3).  188 
 189 
Cardiopulmonary exercise testing 190 
 Exercise tests were conducted on a treadmill (Pro XL, Woodway Inc. WI) using a 191 
graded maximal effort-limited protocol with continuous electrocardiography and breath-192 
by-breath measurement of metabolic gas exchange.  The test protocol consisted of a 2-193 
minute period of standing rest to facilitate ventilatory equilibrium after which treadmill 194 
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speed and gradient were increased to 5 miles.hr-1 (8.0 km.h-1) and 1% respectively for 10 195 
minutes to facilitate musculoskeletal warm up.  After the warm up phase, speed was 196 
maintained at 5 miles hr-1 and gradient increased by 0.5% every 15 s until volitional 197 
exhaustion.  Gas exchange was measured using a commercially available metabolic cart 198 
(Ultima CardiO2; Medgraphics, St.Paul, MN).  Oxygen consumption (V̇O2) data were 199 
smoothed using a 5 breath rolling mean with the highest and lowest values in each 7 200 
breaths removed and peak oxygen consumption (V̇O2peak) was defined as the highest 5 201 
breath mean value during exercise.   The ventilatory threshold was determined by the 202 
modified V-slope method (6).  Heart rate was continuously recorded during exercise 203 
using a wireless 12-lead electrocardiogram system (Mortara X12+ Transmitter; Mortara 204 
Instruments, WI). Primary outcome variables of exercise were time to exhaustion and 205 
V̇O2 peak. 206 
 207 
Carbon Monoxide Rebreathing 208 
 Total hemoglobin mass (tHb-mass) and BV were quantified using the optimized 209 
carbon monoxide (CO) rebreathing method described in detail by Schmidt and Prommer 210 
(26).  In brief, since CO binds avidly to hemoglobin (Hb), carboxyhemoglobin (COHb) 211 
concentration was measured in blood after 2 minutes of rebreathing a known CO volume 212 
(1.0 ml.kg-1 in males and 0.9 ml.kg-1 in females).  Each participant was seated for 15 213 
minutes to allow stabilization of plasma volume, after which a mouthpiece containing 214 
~10g ‘soda lime’ (calcium oxide/sodium hydroxide mixture as a carbon dioxide scrubber) 215 
connected them to a custom made spirometer (Spico-CO Respirations-Applikator, Blood 216 
Tec, Germany) and a 3 litre anesthetic bag pre-filled with 100% oxygen.  The participants 217 
were instructed to completely exhale to residual volume and then take a deep breath in 218 
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through the spirometer while the CO dose was administered into the rebreathing circuit 219 
via a pre-filled 100 ml syringe.  To support the diffusion of CO into the blood, 220 
participants were instructed to perform a 10 second breath hold after the first inspiration, 221 
after which they continued normal breathing from the spirometer for 1 min 50 s.  The 222 
participants were then disconnected from the CO rebreathing circuit after exhaling to 223 
residual volume. The exhaled volume was collected and analyzed to quantify the amount 224 
CO not bound to hemoglobin.  Finally, participants fully exhaled to residual volume into 225 
a CO gas analyzer (Dräger Pac 7000, Drägerwerk AG & Co. KGaA, Germany) before, 226 
and at 4 minutes after CO rebreathing to determine the CO volume exhaled after 227 
disconnecting the patient from the spirometer.  228 
 Fingertip capillary samples (200 μL) were collected before, and at 6- and 8-229 
minutes after the start of CO rebreathing (Na-heparinized 200 μL RAPIDLyte Multicap 230 
Capillary tubes, Siemens Healthcare Diagnostics Inc, Deerfield, USA). Each capillary 231 
blood sample was analyzed in duplicate within 10 minutes of acquisition for 232 
measurement of percent carboxyhemoglobin (%COHb) using a commercially available 233 
blood gas analyzer (ABL80 FLEX CO-OX, Radiometer A/S, Copenhagen, Denmark).  234 
 235 
Calculation of tHb-mass, Blood, Plasma and Erythrocyte Volume 236 
 tHb-mass was calculated using an excel spreadsheet (Microsoft Excel 2011 for 237 
Apple Macintosh) based on the formula: 238 
    tHb-mass = K x MCO(mL) x 100 x (Δ%COHb x 1.39)-1 239 
where:  240 
   K = barometric pressure x 760-1 x [1(0.003661 x temperature)] 241 
   MCO = COadm – (COsystem + lung (after disconnection) + COexhaled (after disconnection)) 242 
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   COadm = CO volume administered into the system 243 
   COsystem + lung (after disconnection) = CO concentration in spirometer x (spirometer volume +  244 
          lung residual volume) 245 
  COexhaled (after disconnection) = end-tidal CO concentration x alveolar ventilation rate 246 
  Δ%COHb = difference between baseline %COHb and %COHb post CO  247 
         administration (average of 6- and 8-min %COHb values) 248 
  1.39 = Hüfners number (constant) (ml CO x g Hb-1) 249 
  Alveolar ventilation rate is assumed to be 5 L.min-1 250 
 251 
 Blood volume, plasma volume and erythrocyte volume were calculated from the 252 
hematocrit, hemoglobin concentration ([Hb]) and tHb-mass using the following formulae: 253 
BV (ml) = tHb-mass (g)/[Hb] (g.dL-1) x 100 254 
Erythrocyte volume (ml) = BV (ml) x hematocrit (%) 255 
Plasma volume (ml) = BV – erythrocyte volume 256 
 257 
 Hematocrit and hemoglobin concentration values were obtained from capillary 258 
blood and were corrected to venous conditions using the following formulae (7, 27): 259 
[Hb] (g.dL-1) = [Hbcapillary] x 0.8787 + 1.24 260 
Hematocrit (%) = [hematocritcapillary] x 0.8425 + 5.23 261 
 262 
 Reproducibility data using identical methodology for tHbmass (standard error = 263 
2.1%) and BV (standard error = 2.4%) were assessed in healthy individuals (n=15) in 264 
preparation for this study.  265 
 266 
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Statistical analysis 267 
 Normality of distribution for all variables was assessed using the Shapiro-Wilk 268 
test. Variables are reported as mean ± standard deviation and median and interquartile 269 
range as appropriate for data distribution. The significance of changes across time points 270 
was assessed using mixed linear modeling with age, V̇O2peak, and gender as fixed effects 271 
and subject identification as a random effect. Akaike’s information criterion tool was 272 
used to select optimal covariance structures for each model. Post hoc pairwise 273 
comparisons of variables between study visits were made using least squares means 274 
derived from the mixed-effects models performed with Bonferroni correction. Linear 275 
regression was used to identify relationships between changes in left and right ventricular 276 
chamber volumes, left and right atrial dimensions, and LV mass, with delta blood volume 277 
and delta plasma volume.  Data analyses were performed using the Statistical Package for 278 
the Social Sciences (SPSS) software version 23 (IBM Corp ©).  A P value of <0.05 was 279 
considered significant.  280 
  281 
RESULTS  282 
 Twenty-one participants (age = 34 ± 7 years, 48% men) completed the 2016 283 
Boston Marathon (4:28 ± 0:27 hours:mins) and then adhered to the 8-week detraining 284 
protocol (Table 1). Running volume decreased from 31.6 ± 9.6 miles.week-1 during the 285 
final marathon training phase to 3.4 ± 3.1 miles.week-1 during weeks 0 to 4 weeks and 4.8 286 
± 3.9 miles.week-1 during weeks 4-8 weeks post-marathon (P<0.001, Figure 2).  At 287 
baseline, LV and RV chamber sizes, as defined using BSA-indexed LV end diastolic 288 
volume and RV end diastolic area, exceeded the upper limits of the clinically 289 
recommended normal range (14), in 6/21 and 7/21 participants respectively.  No runners 290 
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exceeded clinical cut points for LV mass.  V̇O2peak was stable across study time points 291 
but physiologic detraining was evidenced by serial reductions in time to exhaustion 292 
during treadmill testing (baseline = 17.8 min. vs. 4-weeks = 17.3 min. vs. 8-weeks = 17.1 293 
mins, P<0.01).     294 
 295 
4-Weeks Detraining: “Early” Adaptations 296 
 Hematologic and cardiac structural and functional data across study time points 297 
are detailed in Table 2 and Table 3 respectively. After 4-weeks of detraining, BV and 298 
plasma volume were both significantly decreased compared to baseline while erythrocyte 299 
volume and total hemoglobin mass were unchanged. This was accompanied by 300 
significant reductions in LV wall thickness, LV mass, and right atrial size. In contrast, 301 
there were no significant changes in LV chamber dimensions or volume, left atrial 302 
volume, and LV indices of systolic and diastolic function. The majority of RV indices of 303 
size and function were similarly unchanged after 4 weeks of detraining. 304 
 No significant correlations were identified between delta PV and delta BV and 305 
delta LV mass or any chamber volume or area delta values at 4 weeks (R2 values from 306 
0.01-0.14; P values from 0.09 – 0.96).  307 
  308 
8-Weeks Detraining: “Late” Adaptations 309 
 At 8 weeks post-marathon, no further reductions in either blood or plasma volume 310 
were observed, and erythrocyte volume and total hemoglobin mass remained stable. 311 
Similarly, there were no further reductions in LV wall thickness and LV chamber 312 
dimensions remained unchanged. However, there was a significant reduction in RV size 313 
as demonstrated by multiple complementary indices including RV length, basal diameter, 314 
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end-diastolic area, and outflow tract diameter. Aside from the tricuspid annular plane 315 
systolic excursion, which was decreased but remained within normal limits, there were no 316 
statistically significant changes in LV or RV function in systole or diastole at 8 weeks 317 
compared to both previous study time points.  318 
No significant correlations were identified between delta PV and delta BV, and 319 
delta LV mass or any chamber volume or area delta values at the 8-week time point (R2 320 
values from 0.01-0.13; P values from 0.12-0.95).  321 
 322 
323 
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DISCUSSION  324 
 325 
 This longitudinal study, designed to examine the cardiovascular response to 326 
exercise detraining among recreational marathon runners, generated the following 327 
principal findings. Eight weeks of reduced training volume led to a decline in peak 328 
treadmill exercise time, significant reductions in BV, and reverse cardiac remodeling. 329 
Specifically, we observed a 3.6% decline in BV, which was driven by reductions in 330 
plasma volume with concomitant stability of erythrocyte volume and total hemoglobin 331 
mass. This relatively rapid hematologic response occurred early during the study period 332 
and was completed within 4 weeks. In contrast, differential cardiac remodeling occurred 333 
during the two phases of the study period. Specifically, we observed an early and highly 334 
significant reduction in LV mass, driven by reductions in wall thickness, followed by a 335 
subsequent decline in right ventricle size. Contrary to our a priori hypothesis, 336 
hematologic and myocardial changes were not all temporally coupled and associations 337 
between Δ PV and echocardiographic measurements were not significant, with the 338 
exception of a weak association between Δ PV and Δ EF%.  This suggests that reverse 339 
cardiac remodeling, specifically reductions in ventricular chamber dimensions, are not 340 
mechanistically driven by a simple reduction in BV.  In aggregate, these findings provide 341 
novel insights into how the cardiovascular system responds to a sudden and marked 342 
reduction in exercise exposure.  343 
 A large body of prior work has delineated the cardiovascular structural and 344 
functional plasticity in response to endurance exercise training (4, 11). Specifically, 345 
endurance exercise stimulates eccentric remodeling of the left ventricle, right ventricular 346 
dilation, biatrial dilation, and an expansion of BV. These adaptations have been 347 
demonstrated among numerous populations including recreational or novice exercisers 348 
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(1, 13, 28, 35), highly trained and collegiate athletes (23, 33) young elite athletes (18), 349 
and aging masters athletes (10). Comparatively, few studies have examined the reverse 350 
cardiac remodeling associated with physical deconditioning. Important prior work 351 
documents cardiac atrophy during prolonged bed rest, with 60 days of head down tilt bed 352 
rest in healthy females (a similar duration to the present study) and a similar 6-week 353 
study of horizontal bed rest in males reporting highly significant reduction in LV 354 
chamber size (~20%) and LV mass (~8.0%) (9). Similarly, there are several studies 355 
examining elite athletes following termination of training and competition (5, 15, 20), 356 
with one report documenting a 7% decrease in LV cavity dimensions and a 15% decrease 357 
in LV wall thickness after long term (1-13 years) deconditioning (20). These prior data 358 
may represent the upper limits of the reverse remodeling but are not generalizable to the 359 
sizable and rapidly growing population of recreationally exercising people. In addition, 360 
we are unaware of any prior data defining the temporal sequence, right heart 361 
involvement, and role of vascular volume contraction on reverse cardiac remodeling 362 
during detraining.  Findings from this study address each of these key areas of uncertainty 363 
and thereby enhance our understanding of exercise-related cardiac plasticity in several 364 
ways. Our findings suggest that 4 weeks of detraining causes a reduction in left 365 
ventricular wall thickness and that 8 weeks of detraining are sufficient to observe 366 
reductions in right ventricular chamber size. It is noteworthy and perhaps surprising that 367 
we did not observe a reduction in left ventricular chamber dimensions. It is possible that 368 
our study duration was insufficient to capture left ventricular regression, the preceding 369 
training stimulus was not sufficient to cause a significant dilation prior to our detraining 370 
study period, or alternatively, that LV chamber dimensions may be less responsive to 371 
removal of exercise as has been previously suggested. (20). 372 
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 Blood volume, particularly the plasma component, expands acutely in response to 373 
endurance training (16, 24, 31) or during acclimatization to environmental stimuli (22). 374 
To date, few studies have examined changes in BV during exercise detraining and we are 375 
unaware of any work designed to examine the relationship between physiologic BV 376 
fluctuation and myocardial structure and function in this context. While biochemical 377 
mediators and cellular adaptations underlying exercise-induced cardiac remodeling have 378 
been well described (32), the potential role of BV as a physical determinant of cardiac 379 
structure and function in this setting has not been rigorously explored. Based on the 380 
Frank-Starling mechanism, we hypothesized that a significant percentage of the expected 381 
decline in cardiac chamber size would be caused by simple BV or PV contraction.  Our 382 
data refute this hypothesis and suggest that acute reductions in BV or PV during exercise 383 
cessation contribute minimally to reverse cardiac remodeling. While speculative, it is 384 
possible that acute contraction of BV during exercise detraining is coupled with a decline 385 
in peripheral venous capacitance, which facilitates maintenance of central BV. This 386 
speculation is supported by the fact we observed no statistically significant changes 387 
across numerous highly preload dependent indices of myocardial function including 388 
trans-mitral Doppler velocities. Further research designed to explore this potentially 389 
adaptive coupling of the peripheral vasculature with the myocardium represents an 390 
important area of future work. Finally, it is noteworthy that the erythrocyte compartment 391 
of the blood volume: tHbmass, was not significantly different across study timepoints. 392 
The stability of tHbmass parallels our peak V̇O2 data which also did not significantly 393 
decline with detraining as these parameters are well known to be tightly coupled (25).      394 
Given that red cells have a lifespan of approximately 110 days (12), beyond the length of 395 
our study, a longer detraining phase may be required to stimulate a reduction in tHbmass.  396 
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 Several limitations of the present study must be acknowledged.  First, although 397 
our sample size was adequately powered to detect clinically and statistically significant 398 
changes in cardiac morphology during exercise detraining, we lack sufficient numbers to 399 
investigate fully the impact of gender on our observations. While our mixed model 400 
analyses adjusted for gender we cannot exclude the notion that men and women may 401 
respond differently to prescribed detraining. Second, our study period was confined to 8 402 
weeks and included only 2 detraining study time points. Thus we are unable to comment 403 
with any more accuracy than “early” and “late” response regarding the temporal sequence 404 
of our observation. More frequent observations over a more extended time period may 405 
have yielded a more detailed characterization of the detraining response and should be 406 
considered in future similar studies.  Third, we employed a detraining protocol involving 407 
marked reductions in exercise exposure but not complete abstinence. This choice was a 408 
deliberate step to maximize subject recruitment and to make our results generalizable 409 
among individuals who do not stop exercising completely, however, this may have 410 
resulted in Type 2 error.  Fourth, as we previously described exercise-induced cardiac 411 
remodeling during marathon training in a similar cohort, we elected not to study our 412 
current participants during marathon preparation. We are therefore unable to comment on 413 
the completeness of the reverse remodeling we observe during detraining.  Finally, our 414 
cohort was comprised of recreational marathon runners rather than elite or sub-elite 415 
athletes and we are thus unable to comment on how our findings apply to these 416 
specialized populations.  417 
 In conclusion, a sudden and sustained decrease in exercise volume over 8 weeks 418 
results in the regression of exercise-induced cardiac remodeling and a reduced plasma 419 
volume in recreational marathon runners.  This regression follows distinct structure-420 
 18 
specific ‘early’ and ‘late’ time courses characterized by early reductions in LV wall 421 
thickness and mass followed by later reductions in RV chamber size. Contrary to our a 422 
priori hypothesis, contraction of blood volume does not appear to represent a causal 423 
mechanism in the reverse cardiac remodeling during exercise detraining.    424 
 425 
 426 
  427 
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Figure 1. Study design schematic demonstrating periodized marathon training pre- and 545 
in-study exercise exposure and timing of the 3 study visits.   546 
 547 
Figure 2: Weekly training volume during each phase of the study period.  Panel A 548 
represents mean weekly running distance. Error bars represent one standard deviation. 549 
Panel B represents running, cross training (includes stationary bike and elliptical trainer), 550 
yoga and pilates, and weight training duration.  551 
 552 
Figure 3: Schematic diagram of the alterations in blood volume and cardiac morphology 553 
prior to the Marathon and following 4 and 8 weeks of prescribed detraining.  Percentage 554 
changes are detailed only where statistically significant. Downward arrow represents 555 
reduction. RA = right atrium; LA = left atrium; RV = right ventricle; LV = left ventricle; 556 
RVOT = right ventricular outflow tract; BV = blood volume; PV = plasma volume; EV = 557 
erythrocyte volume; LVPW = left ventricle posterior wall; RWT = relative wall 558 
thickness; RVAd = right ventricle area (diastole); RVPLAX = parasternal long axis view 559 
of the right ventricle. 560 
  561 
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Table 1:  Baseline participant characteristics  562 
 All  
(n=21) 
Male  
(n=10) 
Female  
(n=11) 
Age (years) 32.2 (26.4,38.5) 35.3 (28.7,44.1) 27.6 (26.3,36.9) 
Height (cms) 168 (161,174) 175 (172,178) 161 (160,167) 
Weight (kgs) 69.7 (57.7,73.3) 73.6 (72.3,79.6) 57.7 (57.1,62.6) 
BMI (kg.m-2) 23.1 (21.9,25.8) 24.6 (23.3,26.4) 22.2 (20.9,23.0) 
Marathon completion time (hh:mm) 4:21 (4:08,4:51) 4:17 (4:07,4:49) 4:22 (4:10,4:50) 
Baseline V̇O2peak (ml.kg
-1
.min-1) 48.9 (42.2,54.0) 53.6 (46.4,57.1)  47.9 (40.4,49.8)  
Values are presented as median (interquartile range);  BMI = Body Mass Index;  563 
V̇O2peak = Peak oxygen uptake.  564 
565 
 25 
Table 2:  Effects of marathon detraining on body mass, blood volume and exercise 566 
physiology; values presented as median (interquartile range): 567 
Characteristic Pre-marathon + 4 Weeks + 8 Weeks P 
Body mass (kg) mean ± sd 69.4 ± 12.2 69.5 ± 12.8 69.8 ± 12.9 0.294 
Blood volume 
Blood Vol., L 5.0(4.5,6.0) 4.7(4.4,5.9)† 4.8(4.3,6.1) 0.024 
Blood Vol., ml.kg-1 77.9(73.2,81.9) 76.3(69.4,80.2)† 76.3(70.1-79.2) 0.018 
Plasma Vol., L 3.2(3.0,3.6) 3.0(2.8,3.3)† 3.0(2.7-3.6) 0.004 
Plasma Vol., ml.kg-1 47.7(44.9,51.5) 46.1(41.7,48.0)† 45.9(42.8,50.1) 0.003 
Erythrocyte Vol., L 1.7(1.6,2.4) 1.8(1.6,2.5) 1.8(1.6,2.5) 0.745 
Erythrocyte Vol., ml.kg-1 28.5(27.4,31.3) 29.0(27.8,32.4) 28.9(27.3,31.9) 0.903 
tHbmass, ml 563(536,797) 582(531,831) 575(522,833) 0.901 
tHbmass, ml.kg-1 9.5(8.9,10.3) 9.5(9.0,10.7) 9.4(8.9,10.5) 0.977 
Cardiopulmonary Exercise Testing 
TLim, minutes:seconds 17:47(17:10,18:53) 17:23(16:19,18:48) 17:04(16:03,18:18) 0.007 
peak, L.min-1 3.0(2.8,4.2) 3.3(2.8,4.2) 3.3(2.8,4.2) 0.12 
peak, ml.kg-1.min-1 48.9(42.2,48.9) 50.2(48.9,54.6) 49.5(47.1,54.4) 0.08 
peak, L.min-1 111(93.7,153) 109.5(82.2,145.6) 109.5(88.8,150.3) 0.36 
TVT, minutes:seconds 13:14(12:53,14:25) 13:52(12:57,14:37) 13:11(12:43,14:34) 0.42 
VT, L.min
-1 2.45(2.34,3.31) 2.62(2.34,3.25) 2.64(2.38,3.27) 0.16 
P values represent a significant slope across all three measurements. † denotes a highly 568 
significant difference from pre-marathon (P<0.01); Vol. = volume; tHbmass = total 569 
hemoglobin mass; TLim  = Time to exhaustion; peak = maximal aerobic capacity; 570 
peak = maximal ventilation; TVT = time to reach ventilatory threshold; VT = 571 
oxygen uptake at the ventilatory threshold.  572 
 573 
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Table 3a:  Left heart structure and function; values presented as median (interquartile 574 
range): 575 
Characteristic Pre-marathon + 4 Weeks + 8 Weeks P 
Left Heart Structure 
LVIDd, cm 5.0(4.8,5.2) 5.0(4.8,5.2) 5.0(4.7,5.3) 0.777 
LV wall thickness, mm 8(7,8) 7(6,8)† 7(7,8)* 0.02 
LV length, cm  8.5(8.2,9.0) 8.8(8.1,9.0) 8.8(8.4,9.0) 0.26 
RWT, cm 0.30(0.26,0.33) 0.26(0.24,0.32)† 0.29(0.26,0.32)‡ 0.009 
LVEDV, mL  108(96,128) 117(95,121) 110(95,120) 0.843 
LVEDV / BSA, mL/m2 62.1(53.1,69.1) 61.5(55.5,71.7) 61.2(57.3,68.1) 0.859 
LV mass, g 134(109,148) 116(107,134)† 118(106,131)† 0.002 
LV mass / BSA, g/m2 71.8(65.2,80.8) 66.8(60.2,73.0)† 67.2(60.2,71.5)† <0.001 
LA Vol., mL  30(24,39) 29(25,39) 30(27,35) 0.981 
Left Ventricular Function 
Systolic Function     
      Ejection fraction, % 65.2(62.2,67.0) 65.2(63.8,68.8) 64.9(60.9,68.9) 0.182 
      Basal S’, cm.s-1 11(10,13) 11(10,12) 11(10,12) 0.876 
      Longitudinal Strain, % -21.6(-22.8,-20.3) -20.7(-23.4,-20.2) -20.3(-20.2,-18.3) 0.350 
Diastolic Function     
   LV Basal E’, cm.s-1 17(15,18) 16(15,17) 17(15,18) 0.623 
   LV Basal A’, cm.s-1 9(8,10) 9(8,11) 9(8,11) 0.13 
   Trans-mitral E-wave, cm.s-1 0.78(0.72,0.95) 0.80(0.71,0.88) 0.79(0.71,0.93) 0.44 
   Trans-mitral A-wave, cm.s-1 0.39(0.35,0.47) 0.42(0.31,0.49) 0.39(0.30-0.47) 0.854 
   E/A Ratio 1.9(1.6,2.3) 1.8(1.6,2.2) 2.0(1.7,2.6) 0.406 
P values represent a significant slope across all three measurements.  *denotes a 576 
significant difference from pre-marathon (P<0.05); † denotes a significant difference 577 
from pre-marathon (P<0.01); ‡ denotes a significant difference from 4 weeks post 578 
marathon (P<0.05).  LVIDd = left ventricular internal dimension (diastole); LV = left 579 
ventricular; RWT = relative wall thickness; LVEDV = left ventricular end-diastolic 580 
volume; LA = left atrial; S’ = peak systolic tissue velocity ; E’ = early diastolic peak 581 
tissue velocity; A’ = late diastolic peak tissue velocity; E-wave = early mitral inflow 582 
filling velocity; A-wave = late mitral inflow filling velocity; E/A ratio = ratio of early to 583 
late ventricular filling velocities. 584 
 585 
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Table 3b: Right heart structure and function; values presented as median (interquartile 587 
range):  588 
Characteristic Pre-marathon + 4 Weeks + 8 Weeks P 
Right Heart Structure 
RV Length, cm 8.4(7.9,8.9) 8.3(7.9,8.8) 8.0(7.6,8.7)† 0.002 
RV Basal diameter, cm 3.5(3.2,3.9) 3.5(3.3,3.8) 3.4(3.2,3.7)* 0.03 
RVAd, mm2 18.9(15.1,21.0) 18.6(16.4,21.9) 17.5(16.0,21.8)* 0.01 
RVAd / BSA, mm2/m2 10.7(9.5,11.9) 10.9(9.7,11.8) 10.4(9.2,11.4)*‡ 0.02 
RVOT1, cm 3.1(2.7,3.3) 3.0(2.8,3.3) 2.9(2.5,3.0)†‡ 0.015 
RVOT2, cm 2.3(2.0,2.5) 1.9(1.8,2.1)† 1.8(1.7,2.1)† <0.001 
RVPLAX, cm 3.1(2.7,3.4) 3.1(2.6,3.4) 3(2.8,3.2)* 0.014 
RV Strain, % 0.16(0.15,0.17) 0.15(0.14,0.17) 0.15(0.13,0.17 0.615 
RA Area, cm2 11.2(9.9,12.8) 10.8(8.8,12)† 10.5(9.4,12.2)* <0.001 
Right Ventricular Function 
Systole – Right Ventricle     
 RVFAC, % 48.1(45.3,54.7) 49.4(45.7,53.5) 52.1(46.6,55.2) 0.412 
 Basal S’, cm.s-1 0.16(0.15,0.17) 0.15(0.14,0.17) 0.15(0.13,0.17) 0.54 
 TAPSE, mm 2.9(2.6,3.1) 2.8(2.3,3.1) 2.6(2.3,2.9)† 0.012 
P values represent a significant slope across all three measurements.  *significant 589 
difference from pre-marathon (P<0.05); † denotes a significant difference from pre-590 
marathon (P<0.01); ‡ denotes a significant difference from 4 weeks post marathon 591 
(P<0.05). RV = right ventricular; RVAd = right ventricular area in diastole; RVOT1 = 592 
proximal right ventricle outflow tract; RVOT2 = distal right ventricle outflow tract; 593 
RVPLAX = parasternal long axis view of the right ventricle; RA = right atrium; RVFAC 594 
= right ventricular fractional area change; S’ = peak systolic tissue velocity; TAPSE = 595 
tricuspid annular plane systolic excursion. 596 



